Brooks, who was appointed to HemoShear’s Board of Managers in April of 2009, was unanimously elected as Chairman of the Joslin Diabetes Center in May, 2010. Joslin Diabetes Center is a world-renowned teaching and research affiliate of Harvard Medical School, and is responsible for numerous ground-breaking discoveries related to the treatment of diabetes, as well as an innovator in clinical care and education aimed at helping the millions who suffer from the disease.
“I have been involved with the Joslin Center for six years and am proud to serve as Chairman. Diabetes is a growing worldwide epidemic with large consequences for health and society. I hope to make a modest contribution to reversing that trend and to the development of vastly improved treatments and medical care,” said Brooks.
Currently a principal of Healthcare Capital Consulting LLC, Brooks has founded, invested in, and led numerous life sciences businesses. He is a co-founder of Prism Ventureworks, a successful life sciences venture firm which raised more than $1 billion, and co-founded Songbird Hearing, Locus Pharmaceuticals, and Insulet.
“We are proud to have John serve on HemoShear’s Board,” said Jim Powers, HemoShear’s Chairman and CEO. “He has opened many doors for HemoShear in the Boston area and continues to be very active in our strategic planning. We hope to leverage John’s knowledge as HemoShear develops novel human surrogate models of diabetic conditions for discovery of innovative drug treatments for diabetes.”
About HemoShear, LLC
HemoShear’s proprietary technology recreates physiological function of human cells and tissue by applying human-derived blood flow forces to cultures of primary human vascular cells in the laboratory. HemoShear works in strategic partnerships with pharmaceutical companies to identify and validate pathways of disease progression, and to assess the efficacy and safety of new drug compounds. The Company’s breakthrough technology will reduce risk of costly drug development failures significantly while speeding successful new drugs to market. For information about HemoShear, please visit www.hemoshear.com.
